Innate Pharma S.A.
IPHA
$2.03
$0.021.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.51M | 10.03M | 13.65M | 20.26M | 26.89M |
| Total Other Revenue | 7.22M | 7.59M | 8.11M | 8.91M | 9.67M |
| Total Revenue | 13.73M | 17.62M | 21.76M | 29.16M | 36.56M |
| Cost of Revenue | 47.24M | 51.24M | 56.23M | 57.25M | 58.03M |
| Gross Profit | -33.51M | -33.62M | -34.46M | -28.08M | -21.47M |
| SG&A Expenses | 21.65M | 21.27M | 21.33M | 20.85M | 20.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.89M | 72.51M | 77.56M | 78.10M | 78.28M |
| Operating Income | -55.16M | -54.89M | -55.79M | -48.93M | -41.73M |
| Income Before Tax | -50.09M | -51.31M | -53.52M | -45.35M | -36.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.09 | -51.31 | -53.52 | -45.35 | -36.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.09M | -51.31M | -53.52M | -45.35M | -36.82M |
| EBIT | -55.16M | -54.89M | -55.79M | -48.93M | -41.73M |
| EBITDA | -54.16M | -53.70M | -54.39M | -47.32M | -39.92M |
| EPS Basic | -0.60 | -0.62 | -0.66 | -0.56 | -0.46 |
| Normalized Basic EPS | -0.37 | -0.39 | -0.41 | -0.35 | -0.28 |
| EPS Diluted | -0.60 | -0.63 | -0.66 | -0.56 | -0.46 |
| Normalized Diluted EPS | -0.37 | -0.39 | -0.41 | -0.35 | -0.28 |
| Average Basic Shares Outstanding | 336.34M | 330.27M | 324.21M | 323.56M | 322.92M |
| Average Diluted Shares Outstanding | 336.34M | 330.27M | 324.21M | 323.56M | 322.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |